This video is featured in the 2024 ESMO Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub
N

ESMO 2024 Insights: Outcomes in HR+/HER2- eBC by Prior Systemic Therapy - Insights From the NATALEE Trial Subgroup Analysis

By 2024 ESMO Annual Meeting Insights Hub FEATURING Nicholas McAndrew
By 2024 ESMO Annual Meeting Insights Hub FEATURING Nicholas McAndrew
216 views
October 25, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

2024 ESMO Annual Meeting Insights Hub: Breast Videos

06:23

New

ESMO 2024 Insights: Quality-Adjusted Time Without Symptoms or Toxici…

2024 ESMO Annual Meeting Insights Hub

A. Brufsky

13 views
09:23

New

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

2024 ESMO Annual Meeting Insights Hub

P. Fasching

67 views
05:07

New

ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine i…

2024 ESMO Annual Meeting Insights Hub

S. Kim

52 views
View All

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.2K views
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

668 views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.2K views
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.6K views
08:49

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

826 views
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
06:51

New

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

Sara Tolaney

H. Rugo

473 views
15:57

New

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

569 views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

801 views
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.5K views
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
38:49

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

566 views
20:32

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

544 views
21:34

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …

Shabnam Jaffer

725 views
09:12

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

528 views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.4K views
20:25

ESMO 2024 Summary: Highlights in mBC

2024 ESMO Annual Meeting Insights Hub

G. Bianchini

519 views
12:38

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

473 views
AUTOPLAY